University of Florida
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Florida sits in the top decile of US sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count).
University of Florida: 1,106 sponsored US clinical trials, 170 recruiting.
University of Florida sponsors 1,106 registered US clinical trials on ClinicalTrials.gov, 170 of them currently recruiting, and 754 completed. 103 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 17 trials.
Top-decile sponsor footprint
University of Florida ranks in the top decile of sponsors by registered trial count (#29 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
754 of 855 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,106 total, page 14 of 23
Evaluation of Jarro-Dophilus EPS® Probiotic Formulations
NCT02693314
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)
NCT02349672
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
NCT02567461
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
NCT02539160
The Use Of L-Methylfolate As A Treatment For Depression
NCT02133898
Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness
NCT02681081
Novel Mechanisms and Approaches to Treat Neonatal Sepsis
NCT02554630
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
NCT02545933
Dissociating Components of Anhedonia: A Pilot fMRI Study
NCT02569034
Oxytocin Aging Study
NCT02069431
An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma
NCT02591472
Effects of Adding Raisins to the American Diet on Fecal Microbiota Composition
NCT02713165
Electromagnetic Tracking to Measure Tremor
NCT02641366
Cognitive Stimulation Study
NCT02067689
Revitalize Cognition: Near Infrared Stimulation in Older Adults
NCT02582593
Usability of HPV Vaccine Reminders
NCT03987490
Applying Interactive Mobile Health to Asthma Care in Teens (AIM2ACT)
NCT02302040
Diaphragm Pacing After Spinal Cord Injury
NCT02556125
Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population
NCT02338817
Organochlorine Pesticide Exposure in Residents Near Lake Apopka
NCT02530814
Comparison of Smoking and Vaping in Families
NCT02500238
Anesthetic Optimization in Scoliosis Surgery
NCT02481570
rTMS and Botulinum Toxin in Primary Cervical Dystonia
NCT02542839
Motor Learning in Dysphagia Rehabilitation
NCT02576470
Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation
NCT02444052
Uncovering an Electrical Biomarker for Freezing of Gait in Parkinson's Disease
NCT02548897
Respiratory Muscle Function in Untreated X-Linked Myotubular Myopathy (XLMTM)
NCT02453152
Oral Glutathione Supplementation in Older Healthy Adults and Its Effect on the Number of Healthy Days Experienced During Four Months of Supplementation Compared to Placebo
NCT02438956
Role of Provider-at-Triage on ED Efficiency and Quality of Care
NCT02703701
Environment Effect on Six-Minute Walk Test Performance
NCT02502201
A New Adaptive Physical Activity Technology in Older Adults
NCT02467491
Project 4B: Lower Extremity Strength Training in ICU Patients
NCT02467023
Health Professions Students and Faculty Perceptions of Poisoning Severity
NCT02553070
Spinal Manipulative Therapy Treatment Effect Modifiers in Individuals With Low Back Pain
NCT02476383
Relative Bioavailability of Two Different Milk Thistle Formulations
NCT02529605
Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome
NCT02252406
Resveratrol to Enhance Vitality and Vigor in Elders
NCT02123121
Development of Clinical Methods to Evaluate Neural Function in Aging
NCT02073201
1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
NCT02334722
Sensory Processing in Tourette Syndrome
NCT02512406
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine
NCT02403830
rTMS Therapy for Primary Orthostatic Tremor
NCT02441985
Open-Labeled PK-PD Studies of Metoprolol ER
NCT02417246
Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS
NCT02524418
TEMporal PostOperative Pain Signatures
NCT02407743
Safety, Tolerability and Host Response to Lactobacillus Johnsonii
NCT02349360
Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy
NCT02363166
A Pilot Study of Pyridostigmine in Pompe Disease
NCT02357225
Monitoring Postoperative Pain and Recovery Following Orthopedic Surgery
NCT02316951
Novel Stimulation Patterns for the Treatment of Dystonia
NCT02468843
What is open in the University of Florida pipeline
170 recruiting of 1,106 indexed (15% open); 754 completed (68%).
Phase mix: 103 late (III/IV) vs 232 early (I/II) (early-phase heavy).
Top condition: Coronary Artery Disease (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Florida: open-pipeline peers nationwide
Peers matched on 1,106 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Florida sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,106 trials (± recruiting share)
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
- Candel Therapeutics · 15% recruiting · 13 trials
Related
What to do with this University of Florida page
1,106 registered trials is a research-attention snapshot, not an endorsement of University of Florida or any single study.
- 170 of University of Florida's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary Artery Disease is the condition University of Florida studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Florida pipeline card: 1,106 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.